GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHVF) » Definitions » ROE %

Roche Holding AG (Roche Holding AG) ROE %

: 31.84% (As of Dec. 2023)
View and export this data going back to . Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Roche Holding AG's annualized net income for the quarter that ended in Dec. 2023 was $10,086 Mil. Roche Holding AG's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $31,673 Mil. Therefore, Roche Holding AG's annualized ROE % for the quarter that ended in Dec. 2023 was 31.84%.

The historical rank and industry rank for Roche Holding AG's ROE % or its related term are showing as below:

RHHVF' s ROE % Range Over the Past 10 Years
Min: 34.29   Med: 43.18   Max: 48
Current: 41.15

During the past 13 years, Roche Holding AG's highest ROE % was 48.00%. The lowest was 34.29%. And the median was 43.18%.

RHHVF's ROE % is ranked better than
96.6% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.435 vs RHHVF: 41.15

Roche Holding AG ROE % Historical Data

The historical data trend for Roche Holding AG's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.91 43.35 44.82 47.08 41.58

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.99 66.92 29.83 53.29 31.84

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's ROE % distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's ROE % falls into.



Roche Holding AG ROE % Calculation

Roche Holding AG's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=13295.56/( (30047.231+33898.011)/ 2 )
=13295.56/31972.621
=41.58 %

Roche Holding AG's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=10085.568/( (29448.023+33898.011)/ 2 )
=10085.568/31673.017
=31.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Roche Holding AG  (OTCPK:RHHVF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=10085.568/31673.017
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(10085.568 / 68975.486)*(68975.486 / 99157.135)*(99157.135 / 31673.017)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.62 %*0.6956*3.1307
=ROA %*Equity Multiplier
=10.17 %*3.1307
=31.84 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=10085.568/31673.017
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (10085.568 / 11343.664) * (11343.664 / 13022.664) * (13022.664 / 68975.486) * (68975.486 / 99157.135) * (99157.135 / 31673.017)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8891 * 0.8711 * 18.88 % * 0.6956 * 3.1307
=31.84 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Roche Holding AG ROE % Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus

Analysts Tab Veeva Systems as a Top Value Pick

By Barry Cohen 05-25-2022